Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.20% | -4.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.20% | -4.79% | |||
| Cost of Revenue | 4.91% | 8.77% | |||
| Gross Profit | -10.15% | -11.96% | |||
| SG&A Expenses | -1.53% | 8.80% | |||
| Depreciation & Amortization | -1.37% | 0.69% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.02% | 8.60% | |||
| Operating Income | -6.09% | -36.62% | |||
| Income Before Tax | -8.07% | -35.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.07% | -35.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.07% | -35.54% | |||
| EBIT | -6.09% | -36.62% | |||
| EBITDA | -6.52% | -39.53% | |||
| EPS Basic | 36.01% | -2.19% | |||
| Normalized Basic EPS | 36.01% | -2.19% | |||
| EPS Diluted | 36.01% | -2.19% | |||
| Normalized Diluted EPS | 36.01% | -2.19% | |||
| Average Basic Shares Outstanding | 68.91% | 32.64% | |||
| Average Diluted Shares Outstanding | 68.91% | 32.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||